Edition:
United States

Edge Therapeutics Inc (EDGE.OQ)

EDGE.OQ on NASDAQ Stock Exchange Global Select Market

1.25USD
23 Apr 2018
Change (% chg)

$0.11 (+9.65%)
Prev Close
$1.14
Open
$1.15
Day's High
$1.27
Day's Low
$1.13
Volume
160,739
Avg. Vol
167,794
52-wk High
$17.76
52-wk Low
$0.95

Chart for

About

Edge Therapeutics, Inc. is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company's initial product candidates target rare, acute, life-threat... (more)

Overall

Beta: --
Market Cap(Mil.): $35.19
Shares Outstanding(Mil.): 30.87
Dividend: --
Yield (%): --

Financials

  EDGE.OQ Industry Sector
P/E (TTM): -- 188.22 33.60
EPS (TTM): -2.11 -- --
ROI: -70.07 -0.74 13.19
ROE: -85.01 -2.80 15.00

BRIEF-Edge Therapeutics Provides Update Following Interim Analysis

* EDGE THERAPEUTICS PROVIDES UPDATE FOLLOWING INTERIM ANALYSIS OF PHASE 3 NEWTON 2 STUDY OF EG-1962 IN ANEURYSMAL SUBARACHNOID HEMORRHAGE

Mar 28 2018

BRIEF-Edge Therapeutics Reports Qtrly Loss Per Share $0.45

* EDGE THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Mar 01 2018

BRIEF-Edge Therapeutics Says EG-1962 Phase 3 Study Continues As Planned Following Completion Of Futility Analysis

* EDGE'S EG-1962 PHASE 3 NEWTON 2 STUDY CONTINUES AS PLANNED FOLLOWING COMPLETION OF FUTILITY ANALYSIS

Dec 29 2017

BRIEF-Edge Therapeutics reports qtrly loss per share $‍0.37​

* Edge Therapeutics reports third quarter 2017 financial results

Nov 01 2017

Earnings vs. Estimates